LH Labcorp Holdings Inc.

QT69

NYSE·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

353.92

-1.67-0.47%

Overview Short InterestFilings

LHQT69Labcorp Holdings Inc.·NYSE

Overview Short InterestFilings

353.92-0.47%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

DGX-1.50%$247.06 MTD+1.18%$1698.04 GH+2.50%$175.00 ILMN+5.13%$238.21 IQV+1.61%$262.59 MEDP+2.37%$663.49 WAT+2.31%$459.90 RVTY+7.84%$163.48

Snapshot

Index	S&P 500	P/E	29.03	EPS (ttm)	12.19	Insider Own	0.52%	Shs Outstand	81.10M	Perf Week	6.87%

Market Cap	28.70B	Forward P/E	17.94	EPS next Y	19.72	Insider Trans	-4.32%	Shs Float	80.77M	Perf Month	14.67%

Enterprise Value	35.03B	PEG	3.19	EPS next Q	4.49			Short Float	3.17%	Perf Quarter	12.73%

Income	1.00B	P/S	1.97	EPS this Y	13.11%			Short Ratio	3.46	Perf Half Y	37.64%

Sales	14.60B	P/B	3.24	EPS next Y	6.77%	ROA	5.31%	Short Interest	2.56M	Perf YTD	41.07%

Book/sh	109.30	P/C	109.55	EPS next 5Y	9.09%	ROE	11.54%	52W High	371.00 -4.60%	Perf Year	39.36%

Cash/sh	3.23	P/FCF	22.30	EPS past 3/5Y	-9.17% -8.01%	ROIC	7.88%	52W Low	244.52 44.74%	Perf 3Y	77.89%

Dividend Est.	2.88 (0.81%)	EV/EBITDA	16.23	Sales past 3/5Y	5.55% -0.04%	Gross Margin	27.95%	Volatility	4.34% 2.70%	Perf 5Y	45.29%

Dividend TTM	2.88 (0.81%)	EV/Sales	2.40	EPS Y/Y TTM	19.74%	Oper. Margin	11.12%	ATR (14)	9.98	Perf 10Y	194.96%

Dividend Ex-Date	Nov 24, 2026	Quick Ratio	1.22	Sales Y/Y TTM	6.03%	Profit Margin	6.88%	RSI (14)	66.92	Recom	2.26

Dividend Gr. 3/5Y	15.78% —	Current Ratio	1.41	EPS Q/Q	14.35%	SMA20	7.04%	Beta	0.85	Target Price	387.38

Payout	23.65%	Debt/Eq	0.74	Sales Q/Q	6.90%	SMA50	9.27%	Rel Volume	0.98	Prev Close	355.59

Employees	71,000	LT Debt/Eq	0.68	Earnings	Feb 16	SMA200	22.72%	Avg Volume	719.73K	Price	353.92

IPO Date	Mar 29, 1990	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.93% 1.37%	Net Debt/EBITDA	2.93	Volume	704,123	Change	-0.47%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-29-26	Reiterated	Deutsche Bank	Hold	$306 → $355
Oct-29-26	Reiterated	Morgan Stanley	Overweight	$338 → $388
Oct-29-26	Reiterated	Robert W. Baird		$361 → $396
Oct-29-26	Reiterated	UBS	Buy	$380 → $420
Oct-29-26	Reiterated	Truist Securities	Buy	$365 → $395
Oct-28-26	Reiterated	Leerink Partners		$365 → $410
Sep-21-26	Reiterated	Truist Securities	Buy	$320 → $365
Sep-11-26	Reiterated	Barclays	Equal Weight	$320 → $330
Sep-11-26	Reiterated	UBS	Buy	$320 → $380
Aug-10-26	Reiterated	Mizuho Securities	Outperform	$320 → $355

Latest News· Times ET

Oct-30-26

Oct-30-2610:40AM

Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?zacks.com

Oct-29-26

Oct-29-2608:15AM

Labcorp Holdings: The Optimism May Be Going Overboard (Rating Downgrade)seekingalpha.com

Oct-28-26

Oct-28-2604:59PM

Stock Market Today: Dow, Nasdaq Rise After No Fed Rate Hike; Labcorp Blasts OffYahoo

02:50PM

Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcriptseekingalpha.com

01:54PM

Labcorp Targets Margin Growth, Absorbs Policy Headwindsbenzinga.com

01:05PM

Labcorp Q3 Earnings Call Highlightsmarketbeat.com

11:26AM

LH Stock Rises on Q3 Earnings and Revenue Beat, '26 View Upzacks.com

10:31AM

Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metricszacks.com

09:36AM

Labcorp Holdings (LH) Q3 Earnings and Revenues Surpass Estimateszacks.com

06:50AM

Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidanceprnewswire.com

Oct-27-26

Oct-27-2601:36PM

Waters & Labcorp Expand Access to FDA-Approved HPV Screening Testszacks.com

Oct-23-26

Oct-23-2608:00AM

Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026prnewswire.com

Oct-22-26

Oct-22-2604:30PM

Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potentialprnewswire.com

12:41PM

LH vs. DHR: Which Stock Is the Better Value Option?zacks.com

Oct-21-26

Oct-21-2603:34PM

Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and GartnerYahoo

Company

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	14,595	13,952	13,009	12,162	—	—	—	—	—
Cost of Goods Sold Incl. D&A	10,515	10,219	9,385	8,797	—	—	—	—	—
Gross Profit	4,079	3,733	3,624	3,365	—	—	—	—	—
Selling, General and Administrative Excl. Other	2,278	2,216	2,230	2,021	—	—	—	—	—
Research and Development	0	0	0	2	—	—	—	—	—
Other Operating Expense	178	0	308	616	—	—	—	—	—
Operating Income	1,623	1,516	1,087	726	—	—	—	—	—
Interest Expense	230	224	208	200	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-167	-185	81	43	—	—	—	—	—
Net Income Before Taxes	1,225	1,108	960	569	—	—	—	—	—
Income Taxes	220	230	212	189	—	—	—	—	—
Consolidated Net Income	1,005	877	746	418	—	—	—	—	—
Net Income From Continuing Operations	1,005	878	747	380	—	—	—	—	—
Net Income	1,005	877	746	418	—	—	—	—	—
EPS (Recurring)	12.27	10.54	8.89	4.80	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	12.27	10.54	8.89	4.80	—	—	—	—	—
EPS (Diluted)	12.19	10.46	8.84	4.77	—	—	—	—	—
EBITDA	2,158	2,013	1,811	1,349	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	29.03	23.98	25.94	47.65	—	—	—	—	—
Price To Sales Ratio	1.96	1.49	1.48	1.63	—	—	—	—	—
Gross Margin	27.95	26.76	27.86	27.67	—	—	—	—	—
Operating Margin	11.12	10.87	8.36	5.97	—	—	—	—	—
Net Margin	6.89	6.29	5.73	3.44	—	—	—	—	—
Shares Outstanding	81	83	84	87	—	—	—	—	—
Market Capitalization	28,668	20,823	19,263	19,774	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vaughn Bryan T	EVP and President, Diagnostics	Nov 01 '26	Option Exercise	0.00	500	0	7,345	Nov 03
Oyegunwa Akinbolade	EVP, CIO & CTO	Nov 01 '26	Option Exercise	0.00	370	0	5,434	Nov 03
Parham Richelle P	Director	Oct 30 '26	Sale	361.22	1,078	389,395	2,288	Nov 03
ANDERSON KERRII B	Director	Aug 17 '26	Sale	318.02	3,000	954,060	6,563	Aug 18
Schechter Adam H	President & CEO	Aug 11 '26	Sale	320.37	4,669	1,495,808	102,565	Aug 12
Summy Amy B.	EVP, Chief Marketing Officer	Aug 04 '26	Sale	306.74	924	283,428	6,956	Aug 06
Wilkinson Peter J	SVP, Chief Accounting Officer	Aug 03 '26	Option Exercise	209.25	1,338	279,977	3,108	Aug 05
Wilkinson Peter J	SVP, Chief Accounting Officer	Aug 03 '26	Sale	309.23	1,420	439,107	1,770	Aug 05
Kyle Kathryn W	EVP, Chief Legal Officer	Jul 02 '26	Sale	286.19	92	26,329	3,904	Jul 06
Vaughn Bryan T	EVP and President, Diagnostics	Jul 02 '26	Sale	286.19	234	66,968	6,746	Jul 06
Vaughn Bryan T	EVP and President, Diagnostics	Jul 01 '26	Option Exercise	0.00	327	0	7,073	Jul 06
Kyle Kathryn W	EVP, Chief Legal Officer	Jul 01 '26	Option Exercise	0.00	256	0	4,069	Jul 06
Kyle Kathryn W	EVP, Chief Legal Officer	Jun 08 '26	Sale	263.89	762	201,084	3,813	Jun 10
Schechter Adam H	President & CEO	May 11 '26	Sale	254.50	5,903	1,502,314	107,234	May 13
Meltzer Jonathan C	EVP, Operations	Mar 27 '26	Sale	267.05	839	224,055	3,620	Mar 30

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.